CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice

Wu, Xiaobei; Guo, Jialong; Ding, Rui; Lv, Bin; Bi, Liqi

doi:10.1016/j.acthis.2015.09.001

Cited by 27 publications

(18 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the low cell proliferation and less dependence on B-cell activating factor of the tumor necrosis factor family (BAFF), memory B cells have little sensitivity to conventional medication of SLE such as mycophenolate mofetil, cyclophosphamide, and belimumab. [ 13 – 15 ] Several researches had pointed out the possibility of CXCL13-CXCR5 as a target of autoimmune disease: Wu et al [ 16 ] found that CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice. Wiener et al [ 17 ] also reported that the substantial improvement was observed after CXCR5 knockout in lpr mice.…”

Section: Discussionmentioning

confidence: 99%

The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus

Fang

Luo²,

Li³

2017

Medicine

View full text Add to dashboard Cite

We investigated whether serum CXC ligand 13 protein (CXCL13) levels correlate with the circulating plasmablasts and memory B-cells alteration in systemic lupus erythematosus (SLE) patients. The diagnostic use of CXCL13 concentrations in active lupus was also analyzed.A total of 36 SLE patients and 18 healthy controls were included. Serum CXCL13 levels were examined by enzyme-linked immunosorbent assay. The frequency and absolute count of circulating plasmablasts and memory B cells were analyzed by flow cytometry. Receiver operating characteristic curves (ROC curves) were generated to analyze the utility of serum CXCL13 level and plasmablasts frequency as tools for the recognition of active SLE.Elevation of serum CXCL13 levels, higher plasmablasts frequency, and reduction of memory B-cells count were observed in SLE patients, compared with healthy controls. Interestingly, correlational analyses showed not only significantly positive association between CXCL13 levels and SLE Disease Activity Index (SLEDAI) or plasmablasts frequency, but an inverse correlation between CXCL13 concentration and memory B-cell count. ROC curves showed that serum CXCL13 level and plasmablasts frequency were practical in identifying active disease from overall SLE patients, with considerable accuracy.Serum CXCL13 levels correlate with the alteration of plasmablasts and memory B cells in SLE. CXCL13 may be used as a practical tool in judgment of active SLE.

show abstract

Section: Discussionmentioning

confidence: 99%

The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus

Fang

Luo²,

Li³

2017

Medicine

View full text Add to dashboard Cite

show abstract

“…Research performed in NZB/W-F1 mice and LN patients [4] suggested that CXCL13 played an important role in the initiation and development of LN as a B-lymphocyte chemokine. Whether CXCL13 is related to the renal pathological damage observed in LN and the formation of abnormal B-lymphocyte infiltration-related ELT have not been reported in detail [8, 9]. …”

Section: Introductionmentioning

confidence: 99%

Association of Serum CXCL13 with Intrarenal Ectopic Lymphoid Tissue Formation in Lupus Nephritis

Chen

Long

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

Aims. To assess the concentrations of serum CXCL13 and intrarenal ectopic lymphoid tissue (ELT) profiles and their correlation in the patients with lupus nephritis (LN). Methods. Serum CXCL13 levels were measured using enzyme-linked immunosorbent assays (ELISA). The expression of CD3, CD20, and CD21 in renal biopsy specimens was tested using immunohistochemical methods. Results. Serum CXCL13 levels were significantly higher in the LN group than those in the SLE group without LN and also in the type III and IV LN patients than in type V LN patients. LN patients with positive CD20 expression (CD20+ LN) had a longer disease course and poorer response to combination therapy and higher serum CXCL13 levels than CD20− LN patients. Moreover, the serum CXCL13 level was positively correlated with the number of B cells/HP in the renal tissue of LN patients. The coexpression patterns of CD3, CD20, and CD21 in the renal tissue of LN patients with different WHO pathological types were significantly different. Serum CXCL13 levels were significantly higher in ELT-2 type LN patients than in 0 or 1 type LN patients. Conclusions. This study suggested that increased serum levels of CXCL13 might be involved in renal ELT formation and renal impairment process in LN.

show abstract

“…Recently, the prognosis of SLE patients with nephropathy has been markedly improved by the therapy of immunosuppressive. However, the definite strategies for LN treatment remain undefined, and there is still many of patients progress to the end-stage renal disease [8, 10, 11]. Thus, developing an inexpensive natural agents that possesses the protective effects for LN patients is further a higher challenge.…”

Section: Introductionmentioning

confidence: 99%

Reno-protective effect and mechanism study of Huang Lian Jie Du Decoction on lupus nephritis MRL/lpr mice

Nie

Deng

Xiang

et al. 2016

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundHuang Lian Jie Du Decoction (HLJDD), a very famous traditional Chinese medicinal prescription, has been used for heat dissipation and detoxification in China. This study was aimed to evaluate the reno-protective effects of HLJDD against lupus nephritis (LN) in vivo in MRL/lpr mice.MethodsAnimals were administered orally every day for eight consecutive weeks except the mice of normal group and model group. Organ indexes, serum interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-gamma (IFN-γ) and the anti-double stranded DNA (anti-dsDNA) antibody were tested, respectively. Creatinine (Cr), blood urea nitrogen (BUN) and urine protein were measured for renal function evaluation. The expression of phosphorylated signal transducer and activator of transcription 3 (p-STAT 3) in kidney tissue was observed by western blot (WB) and immunohistochemical (IHC) method. Meanwhile, histopathological changes in the renal were studied by hematoxylin-eosin (H&E) staining.ResultsThe mice of HLJDD-treated group exhibited a significant reduced mortality (p < 0.05), serum anti-dsDNA level (p < 0.05) and renal immune complex deposition (p < 0.05), compared with the untreated MRL/lpr mice. In addition, HLJDD treatment remarkably reduced the levels of BUN, Cr, proteinuria (p < 0.01) and the levels of inflammatory cytokines such as IL-6, IL-10 and IFN-γ (p < 0.01). Moreover, HLJDD significantly suppressed the phosphorylations of STAT 3 (p < 0.05) and the renal pathological changes.ConclusionsThe study implied that HLJDD may be a potential agent for the therapy of LN, and the down-regulated p-STAT 3 expression suggesting that it may be one of the LN therapy targets for HLJDD.

show abstract

CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice

Cited by 27 publications

References 37 publications

The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus

The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus

Association of Serum CXCL13 with Intrarenal Ectopic Lymphoid Tissue Formation in Lupus Nephritis

Reno-protective effect and mechanism study of Huang Lian Jie Du Decoction on lupus nephritis MRL/lpr mice

Contact Info

Product

Resources

About